KayoThera

About:

KayoThera develops therapeutics used to cure late-stage and metastatic cancers.

Twitter/X: kayothera

Top Investors: BioAdvance, WRF Capital, 7G Bioventures, National Institute of General Medical Science, Accelerator Life Science Partners

Description:

KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is to develop the first-in-class immuno- and targeted therapies to drive cures in advanced cancers KayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.

Total Funding Amount:

$14M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Princeton, New Jersey, United States

Founded Date:

2019-01-01

Founders:

Mark Esposito, Yibin Kang

Number of Employees:

11-50

Last Funding Date:

2023-07-19

IPO Status:

Private

Industries: